Brazil's cancer centres command high equipment spends:
This article was originally published in Clinica
Investments in new equipment for Brazil's latest high-tech cancer centre reached R$3.7 million (US$1.6 million) of the R$4.5 million total set-up cost. The Centro de Alta Complexidade em Oncologia (Cacon) of the Governador Jo-o Alves Filho hospital in Arauju, state of Sergipe, is an example of Brazil's commitment to improve levels of cancer care. In line with the rest of the network of centres being set up under the ongoing Expande programme (see Clinica No 995, p 15), it has been equipped with new radiodiagnostic, mammography and brachytherapy facilities and a linear accelerator. The Arauju centre, just opened, aims to provide the latest diagnostics, haemotherapy, radiotherapy and clinical and surgical oncology services to around 600 patients daily, from Sergipe and neighbouring states.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.